Challenges and solutions for therapeutic TCR‐based agents
Recent development of methods to discover and engineer therapeutic T‐cell receptors
(TCRs) or antibody mimics of TCRs, and to understand their immunology and …
(TCRs) or antibody mimics of TCRs, and to understand their immunology and …
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a “Trojan Horse”
DS Karpov, AO Sosnovtseva, SV Pylina… - International Journal of …, 2023 - mdpi.com
Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by the destruction of
insulin-producing β-cells in the pancreas by cytotoxic T-cells. To date, there are no drugs …
insulin-producing β-cells in the pancreas by cytotoxic T-cells. To date, there are no drugs …
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
D Lainšček, A Golob-Urbanc, V Mikolič… - Molecular Therapy …, 2023 - cell.com
CAR-T cells present a highly effective therapeutic option for several malignant diseases,
based on their ability to recognize the selected tumor surface marker in an MHC …
based on their ability to recognize the selected tumor surface marker in an MHC …
Chimeric antigen receptor T cells march into T cell malignancies
J Tang, X Zhao - Journal of Cancer Research and Clinical Oncology, 2023 - Springer
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in
humans arising from aberrant T cells. Such malignancies are often associated with poor …
humans arising from aberrant T cells. Such malignancies are often associated with poor …
[HTML][HTML] CAR T-Cell Therapy: A New Era in Cancer Immunotherapy
M Sahlolbei, A Ahmadieh-Yazdi, M Rostamipoor… - 2024 - intechopen.com
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of
cancer immunotherapy, offering a targeted approach to combat various hematologic …
cancer immunotherapy, offering a targeted approach to combat various hematologic …